KR900015754A - 전암 병소 전신요법용의 적어도 1종의 사이토킨을 함유하는 약제학적 조성물의 용도 - Google Patents

전암 병소 전신요법용의 적어도 1종의 사이토킨을 함유하는 약제학적 조성물의 용도 Download PDF

Info

Publication number
KR900015754A
KR900015754A KR1019900004955A KR900004955A KR900015754A KR 900015754 A KR900015754 A KR 900015754A KR 1019900004955 A KR1019900004955 A KR 1019900004955A KR 900004955 A KR900004955 A KR 900004955A KR 900015754 A KR900015754 A KR 900015754A
Authority
KR
South Korea
Prior art keywords
cytokine
mixture
cytokines
pharmaceutical composition
precancerous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019900004955A
Other languages
English (en)
Korean (ko)
Inventor
보니버 쟈크스
Original Assignee
디터 라우딘, 루돌프 호프만
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디터 라우딘, 루돌프 호프만, 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 디터 라우딘, 루돌프 호프만
Publication of KR900015754A publication Critical patent/KR900015754A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
KR1019900004955A 1988-04-11 1990-04-11 전암 병소 전신요법용의 적어도 1종의 사이토킨을 함유하는 약제학적 조성물의 용도 Ceased KR900015754A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE39217200 1988-04-11
DE3911720 1989-04-11
DE4005416 1990-02-21
DE4005416.0 1990-02-21

Publications (1)

Publication Number Publication Date
KR900015754A true KR900015754A (ko) 1990-11-10

Family

ID=25879777

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900004955A Ceased KR900015754A (ko) 1988-04-11 1990-04-11 전암 병소 전신요법용의 적어도 1종의 사이토킨을 함유하는 약제학적 조성물의 용도

Country Status (14)

Country Link
US (1) US5128126A (cg-RX-API-DMAC7.html)
EP (1) EP0392300B1 (cg-RX-API-DMAC7.html)
JP (1) JPH02304027A (cg-RX-API-DMAC7.html)
KR (1) KR900015754A (cg-RX-API-DMAC7.html)
AT (1) ATE79763T1 (cg-RX-API-DMAC7.html)
AU (1) AU638982B2 (cg-RX-API-DMAC7.html)
CA (1) CA2014130A1 (cg-RX-API-DMAC7.html)
DE (1) DE59000270D1 (cg-RX-API-DMAC7.html)
DK (1) DK0392300T3 (cg-RX-API-DMAC7.html)
ES (1) ES2034790T3 (cg-RX-API-DMAC7.html)
GR (1) GR3005528T3 (cg-RX-API-DMAC7.html)
HU (1) HU206834B (cg-RX-API-DMAC7.html)
IE (1) IE64765B1 (cg-RX-API-DMAC7.html)
IL (1) IL94052A (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
JP2597953B2 (ja) * 1991-12-10 1997-04-09 大塚製薬株式会社 制癌剤
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
WO1999040929A1 (en) * 1998-02-12 1999-08-19 The General Hospital Corporation Methods to potentiate cancer therapies
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
EP1803730A1 (en) * 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20040247565A1 (en) * 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US20050118138A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
EP1318834A2 (en) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CA2442971C (en) * 2001-04-06 2011-06-07 University Of Chicago Chemotherapeutic induction of egr-1 promoter activity
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
EP1691852A2 (en) * 2003-11-10 2006-08-23 Angiotech International AG Medical implants and fibrosis-inducing agents
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
EP1781284B1 (en) * 2004-08-25 2010-10-13 The University of Chicago Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
EP1977759A1 (en) * 2007-03-27 2008-10-08 4Sc Ag Pharmaceutical composition comprising a cytokine
US20080241100A1 (en) * 2007-03-27 2008-10-02 Stefan Strobl Pharmaceutical composition comprising a cytokine
CA2682050A1 (en) * 2007-03-27 2008-10-02 4Sc Ag Pharmaceutical composition comprising a cytokine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9051882A (en) * 1981-10-08 1983-04-27 Berg, Kurt Frimann Method and composition for treating a patient suffering from interferon-susceptible disorders
WO1983001198A1 (en) * 1981-10-08 1983-04-14 Kurt Frimann Berg Method and composition for treating a patient suffering from interferon-susceptible disorder
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
DE3278234D1 (en) * 1981-10-13 1988-04-21 Exovir Inc Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Also Published As

Publication number Publication date
IL94052A0 (en) 1991-01-31
ES2034790T3 (es) 1993-04-01
DK0392300T3 (da) 1992-09-28
CA2014130A1 (en) 1990-10-11
JPH02304027A (ja) 1990-12-17
EP0392300B1 (de) 1992-08-26
IE901297L (en) 1990-10-11
US5128126A (en) 1992-07-07
ATE79763T1 (de) 1992-09-15
DE59000270D1 (de) 1992-10-01
AU5310590A (en) 1990-10-18
HU206834B (en) 1993-01-28
AU638982B2 (en) 1993-07-15
IE64765B1 (en) 1995-09-06
HU902145D0 (en) 1990-07-28
IL94052A (en) 1995-06-29
EP0392300A1 (de) 1990-10-17
GR3005528T3 (cg-RX-API-DMAC7.html) 1993-06-07
HUT54303A (en) 1991-02-28

Similar Documents

Publication Publication Date Title
KR900015754A (ko) 전암 병소 전신요법용의 적어도 1종의 사이토킨을 함유하는 약제학적 조성물의 용도
KR900001362A (ko) 마이크로-입자 및/또는 나노-입자로 구성된 신규한 고체 다공성 단위형태 및 그것의 제조
ATE61227T1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
DE3271829D1 (en) An allergen dry powder composition and process for its preparation
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
KR880008800A (ko) 난용성 활성성분을 위한 치료계
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
ATE102047T1 (de) Pharmazeutische zusammensetzung enthaltend interferon fuer bukkale verabreichung.
JO1365B1 (en) Laoxy repo nucleic polypeptide acid has a physiological activity on humans and includes a basic sequence for the coded arrangement of the said polypeptide and a method for producing this for polypeptide and the pharmacological composition included.
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
ATE353009T1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
KR880010776A (ko) 림포킨 및 이중-가닥 rna의 상승 작용화 조성물
Ariel Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors
KR910005858A (ko) 지방산 요법
SE7601535L (sv) Injicerbara antibiotiska kompositioner
RU93032615A (ru) Композиции для воздействия на опухолевые клетки, способ обработки опухолевых клеток
KR910018038A (ko) 원발성 흉막암의 치료를 위한 제약 조성물 제조용 인체 인터루킨 2활성 함유 폴리펩티드의 용도
KR890000108A (ko) 종양 치료용 약제학적 조성물
KR900017599A (ko) 종양 치료용 약학 조성물
KR870011135A (ko) 시스-6-(4-아세트아닐리도)-8,9-디메톡시-2-메틸-1,2,3,4,4a,10b- 헥사이드로-벤조〔c〕〔1,6〕 나프티리딘으로 구성된 약학적 조성물 및 그것의 용도
KR890015746A (ko) 메게스트롤 아세테이트로 aids 악액질을 치료하는 방법
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
KR0169975B1 (ko) 감마 인터페론 활성을 갖는 폴리펩티드를 함유하는 원발성 흉막암 치료용 제약 조성물
DE69530779T2 (de) Muramylpeptide zusammensetzungen für inhibierung von hiv replikation

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900411

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950327

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19900411

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980223

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19980518

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19980223

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I